JoomFish-Language Selection
|
Cytokinetics announced today that its drug CK-2017357 has been granted orphan-drug designation by FDA. The drug is in trials for amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease), a condition that affects about 20,000 to 30,000 people in the U.S. Cytokinetics plans to initiate a Phase II trial for CK-2017357 in ALS patients in the first half of 2010. Cytokinetics release |
Partenaires sponsors
Sanofi Aventis
Merck & Co
Groupe LFB
Santeos
Partenaires
Commission Européenne
Commission Européenne
Agence Nationale de la recherche
HAS
Inserm
Ministère de l'enseignement supérieur et de la recherche
Medicen Paris région
Angels santé
Actelion pharmaceuticals
Biopharmaceutiques
Cerenis therapeutics
CISS
Fovea pharmaceuticals
IMS Health
Janssen Cilag
Nixon Peabody
Paris Biotech Santé
Pharmaceutiques
Px therapeutics
Biocitech
Actulabo
Actulabo
